» Articles » PMID: 30130791

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram

Abstract

Objective: We built and externally validated a nomogram for predicting the overall survival (OS) probability of advanced gastric cancer patients receiving second-line treatment.

Methods: The nomogram was developed on a set of 320 Italian patients and validated on two independent sets (295 Italian and 172 Korean patients). Putative prognostic variables were selected using a random forest model and included in the multivariable Cox model. The nomogram's performance was evaluated by calibration plot and C index.

Results: ECOG performance status, neutrophils to lymphocytes ratio, and peritoneal involvement were selected and included into the multivariable model. The C index was 0.72 (95% CI 0.68-0.75) in the development set, 0.69 (95% CI 0.65-0.73) in the Italian validation set, but only 0.57 (95% CI 0.52-0.62) in the Korean set. While Italian calibrations were quite good, the Korean one was poor. Regarding 6-month OS predictions, calibration was best in both Caucasian cohorts and worst the in Asian one.

Conclusions: Our nomogram may be a useful tool to predict 3- or 6-month OS in Caucasian gastric cancer patients eligible for second-line therapy. Based on three easy-to-collect variables, the Gastric Life nomogram may help clinicians improve patient selection for second-line treatments and assist in clinical trial enrollment.

Citing Articles

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion.

Cascinu S, Di Bartolomeo M, Lonardi S, Beretta G, Fornaro L, De Vita F Front Med (Lausanne). 2023; 9:1002435.

PMID: 36590964 PMC: 9799163. DOI: 10.3389/fmed.2022.1002435.


SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy.

Kuijper S, Pape M, Haj Mohammad N, van Voorthuizen T, Verhoeven R, van Laarhoven H Int J Cancer. 2022; 152(6):1202-1209.

PMID: 36451334 PMC: 10107625. DOI: 10.1002/ijc.34385.


Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.

Fuca G, Cohen R, Lonardi S, Shitara K, Elez M, Fakih M J Immunother Cancer. 2022; 10(2).

PMID: 35110358 PMC: 8811606. DOI: 10.1136/jitc-2021-004001.


A nomogram to predict overall survival and disease-free survival after curative-intent gastrectomy for gastric cancer.

Tonello A, Capelli G, Bao Q, Marchet A, Farinati F, Pawlik T Updates Surg. 2021; 73(5):1879-1890.

PMID: 34125428 PMC: 8500903. DOI: 10.1007/s13304-021-01083-7.


Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN).

Fornaro L, Spallanzani A, De Vita F, Dugo D, Falcone A, Lorenzon L Cancers (Basel). 2021; 13(6).

PMID: 33804024 PMC: 8001719. DOI: 10.3390/cancers13061304.